Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096234 · ClinicalTrials.gov registry record · Phase 1
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05096234: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT05096234 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096234, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Interventions
- DRUG [ 18F]F-AraG PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2023-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096234
The ClinicalTrials.gov registry entry for NCT05096234 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [ 18F]F-AraG PET is the first listed.
NCT05096234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096234 about?
NCT05096234 is a clinical study titled "18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma". This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
What is the current status of trial NCT05096234?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-09-28. Estimated completion is 2023-10-09.
What interventions are being tested in trial NCT05096234?
The interventions under investigation include: [ 18F]F-AraG PET (DRUG).
Who is sponsoring clinical trial NCT05096234?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.